Genotoxicity of advanced glycation end products in mammalian cells

Cancer Letters

Volumn 190, Issue 2, 2003, Pages 151-156

  Stopper, Helga ^a   Schinzel, Reinhard ^a   Sebekova, Katarina ^b   Heidland, August ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

Author keywords

Advanced glycation end product; Comet assay; DNA damage

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BOVINE SERUM ALBUMIN; BROMELAIN; CARBOXYMETHYLLYSINE; CELL DNA; LYSINE DERIVATIVE; METHYLGLYOXAL; REACTIVE OXYGEN METABOLITE; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL STRAIN; CHRONIC KIDNEY FAILURE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; GENOTOXICITY; INCUBATION TIME; KIDNEY TUBULE CELL; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING;

BOVINAE; MAMMALIA; SUS SCROFA;

EID: 0037455982     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00626-2     Document Type: Article

References (25)

1. Maisonneuve P., Agodoa L., Gellert R., Stewart J.H., Buccianti G., Lowenfels A.B., Wolfe R.A., Jones E., Disney A.P., Briggs D., McCredie M., Boyle P. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 354:1999;93-99.
2. Heidland A., Bahner U., Vamvakas S. Incidence and spectrum of dialysis-associated cancer in three continents. Am. J. Kidney Dis. 35:2000;347-351.
3. Stopper H., Meysen T., Bockenforde A., Bahner U., Heidland A., Vamvakas S. Increased genomic damage in lymphocytes of patients before and after long-term maintenance hemodialysis therapy. Am. J. Kidney Dis. 34:1999;433-437.
4. Stopper H., Boullay F., Heidland A., Vienken J., Bahner U. Comet-assay analysis identifies genomic damage in lymphocytes of uremic patients. Am. J. Kidney Dis. 38:2001;296-301.
5. Schleicher E.D., Bierhaus A., Haring H.U., Nawroth P.P., Lehmann R. Chemistry and pathobiology of advanced glycation end products. Contrib. Nephrol. 131:2001;1-9.
6. Heidland A., Sebekova K., Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am. J. Kidney Dis. 38:2001;S100-S106.
7. Baynes J.W. The role of AGEs in aging: causation or correlation. Exp. Gerontol. 36:2001;1527-1537.
8. Schleicher E.D., Wagner E., Nerlich A.G. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 99:1997;457-468.
9. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 414:2001;813-820.
10. Pischetsrieder M., Seidel W., Munch G., Schinzel R. N(2)-(1-carboxyethyl)deoxyguanosine, a nonenzymatic glycation adduct of DNA, induces single-strand breaks and increases mutation frequencies. Biochem. Biophys. Res. Commun. 264:1999;544-549.
11. Seidel W., Pischetsrieder M. DNA-glycation leads to depurination by the loss of N2-carboxyethylguanine in vitro. Cell. Mol. Biol. (Noisy-le-Grand). 44:1998;1165-1170.
12. Kassie F., Parzefall W., Knasmuller S. Single cell gel electrophoresis assay: a new technique for human biomonitoring studies. Mutat. Res. 463:2000;13-31.
13. Schmidt A.M., Hasu M., Popov D., Zhang J.H., Chen J., Yan S.D., Brett J., Cao R., Kuwabara K., Costache G., Simionescu N., Stern D. Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Natl. Acad. Sci. USA. 91:1994;8807-8811.
14. Reddy S., Bichler J., Wells-Knecht K.J., Thorpe S.R., Baynes J.W. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry. 34:1995;10872-10878.
15. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175:1988;184-191.
16. Bucala R., Lee A.T., Rourke L., Cerami A. Transposition of an Alu-containing element induced by DNA-advanced glycosylation endproducts. Proc. Natl. Acad. Sci. USA. 90:1993;2666-2670.
17. Xiang G., Schinzel R., Simm A., Munch G., Sebekova K., Kasper M., Niwa T., Schmitz C., Heidland A. Advanced glycation end products (AGEs)-induced expression of TGF-beta 1 is suppressed by a protease in the tubule cell line LLC-PK1. Nephrol. Dial. Transplant. 16:2001;1562-1569.
18. Schmidt A.M., Stern D.M. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol. Metab. 11:2000;368-375.
19. Kislinger T., Fu C., Huber B., Qu W., Taguchi A., Du Yan S., Hofmann M., Yan S.F., Pischetsrieder M., Stern D., Schmidt A.M. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274:1999;31740-31749.
20. Yan S.D., Schmidt A.M., Anderson G.M., Zhang J., Brett J., Zou Y.S., Pinsky D., Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269:1994;9889-9897.
21. Bierhaus A., Illmer T., Kasper M., Luther T., Quehenberger P., Tritschler H., Wahl P., Ziegler R., Mueller M., Nawroth P.P. Advanced glycation end product-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation. 96:1997;2262-2271.
22. Marnett L.J. Oxyradicals and DNA damage. Carcinogenesis. 21:2000;361-370.
23. Epe B., Hegler J., Wild D. Identification of ultimate DNA damaging oxygen species. Environ. Health Perspect. 88:1990;111-115.
24. Saxena A.K., Saxena P., Wu X., Obrenovich M., Weiss W.F., Monnier V.M. Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress. Biochem. Biophys. Res. Commun. 260:1999;332-338.
25. Seidel W., Pischetsrieder M. Immunochemical detection of N2-[1-(1-carboxy)ethyl]guanosine, an advanced glycation end product formed by the reaction of DNA and reducing sugars or L-ascorbic acid in vitro. Biochim. Biophys. Acta. 1425:1998;478-484.